+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Somatostatin Analogs Market - Global Forecast to 2030- Product Image
Somatostatin Analogs Market - Global Forecast to 2030- Product Image
Sale

Somatostatin Analogs Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5337116
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Somatostatin Analogs Market grew from USD 7.49 billion in 2024 to USD 8.30 billion in 2025. It is expected to continue growing at a CAGR of 10.36%, reaching USD 13.54 billion by 2030.

The somatostatin analogs sector has emerged as a critical frontier in the management of neuroendocrine tumors, acromegaly and pituitary disorders, driven by unmet clinical needs and advances in peptide engineering. As treatment paradigms evolve, long-acting formulations and novel delivery systems such as pre-filled syringes and emerging oral and nasal platforms are reshaping patient experiences and adherence. This growing complexity is further fueled by regulatory developments across major markets, reimbursement pressures and the entry of biosimilars, which collectively challenge traditional commercial strategies.

Stakeholders-including pharmaceutical innovators, contract development organizations and healthcare providers-must navigate a dynamic environment marked by shifting payer policies, supply chain vulnerabilities and accelerating technological breakthroughs. In this context, a deep analysis of market drivers, competitive positioning and patient demographics becomes essential for informed decision-making. This executive summary synthesizes transformative shifts, segmentation insights, regional dynamics, company profiles and strategic recommendations to equip leaders with a comprehensive understanding of the somatostatin analogs landscape.

Key Transformative Shifts Reshaping the Somatostatin Analogs Landscape

Over the past decade, the somatostatin analogs landscape has been redefined by several transformative shifts. The transition from immediate-release injections to long-acting depot formulations and pre-filled syringes has improved dosing convenience and reduced clinic visit frequency, driving stronger patient compliance. Concurrently, advances in formulation science have enabled development of direct nasal applications and controlled-release oral pills, heralding a new era of non-invasive therapy options.

At the same time, precision medicine initiatives and digital health solutions are integrating real-time monitoring of biomarkers and patient outcomes, enhancing therapeutic customization. Manufacturers are forging collaborations to leverage bioconjugation methods, solid-phase synthesis and recombinant DNA technology, accelerating pipeline diversification. Regulatory authorities have responded with streamlined approval pathways for orphan indications, while pricing reforms and value-based contracting models are compelling firms to demonstrate real-world evidence of efficacy and cost-effectiveness.

Taken together, these forces are not only elevating clinical standards but also recalibrating competitive strategies. Industry participants that anticipate and adapt to these shifts will secure sustainable growth in an increasingly complex and patient-centric market.

Assessing the 2025 United States Tariff Impact on Somatostatin Analog Supplies

In 2025, proposed increases in United States import tariffs on peptide therapeutics are poised to introduce significant headwinds for somatostatin analogs. As raw materials and active pharmaceutical ingredients are predominantly sourced from global manufacturing hubs, cumulative tariff burdens risk inflating production costs and pressuring manufacturer margins. This, in turn, could translate into higher list prices or reduced rebates, potentially impacting patient access and reimbursement negotiations.

Moreover, supply chain realignment in response to tariffs may trigger delays and bottlenecks, especially for firms reliant on single-source suppliers. To mitigate risks, leading organizations are evaluating near-shoring strategies, diversifying their supplier base, and investing in domestic manufacturing capabilities. They are also intensifying policy engagement to advocate for exemptions on critical peptide imports and seeking bilateral agreements to stabilize trade flows.

Ultimately, companies that develop agile supply chain frameworks, optimize cost structures and proactively engage with policymakers will be best positioned to navigate the cumulative effects of 2025 tariff reforms, ensuring continuity of supply and competitive pricing for somatostatin analog therapies.

Insights from Segmentation by Drug Type, Application, End-User, Formulation, Technology, and Demographics

Market segmentation provides a nuanced view of growth drivers and adoption patterns across multiple dimensions. In terms of drug types, Lanreotide-offered in both depot form and pre-filled syringes-continues to capture significant market share, while Octreotide maintains relevance through immediate-release and long-acting formulations, and Pasireotide expands its footprint via intramuscular and subcutaneous routes.

From the end-user perspective, distribution channels encompass general clinics alongside specialty clinics, with private and public hospitals providing inpatient and outpatient services, and research institutes driving innovation across both biotechnology and pharmaceutical research domains.

Application segmentation reveals a balanced demand between oncology indications, notably acromegaly and neuroendocrine tumors, and pituitary disorders including Cushing’s disease and gigantism, underscoring the therapeutic versatility of somatostatin analogs.

Formulation preferences indicate a sustained dominance of injectable solutions, an emerging uptake of direct nasal spray delivery, and a growing interest in oral pills, particularly those engineered for controlled-release, alongside conventional immediate-release tablets.

On the technology front, bioconjugation methods emphasize peptide backbone modification to enhance stability and half-life, chemical synthesis techniques include both liquid-phase and solid-phase approaches for scalable production, and recombinant DNA technology leverages eukaryotic and prokaryotic expression systems to optimize yield and purity.

Finally, patient demographics shape market dynamics by distinguishing adult subpopulations-elderly patients requiring simplified dosing regimens and working professionals seeking minimal disruption-and pediatric cohorts spanning adolescent and pre-adolescent groups where safety and tolerability profiles are paramount.

Regional Dynamics Driving Growth in the Somatostatin Analogs Market

Regional analysis highlights distinct trends across the Americas, Europe Middle East & Africa (EMEA), and Asia-Pacific regions, each with unique drivers and challenges. In the Americas, robust healthcare infrastructure, well-established reimbursement frameworks and a high prevalence of neuroendocrine tumor diagnoses accelerate uptake of advanced somatostatin analog therapies. Manufacturers benefit from streamlined regulatory pathways and a mature contract manufacturing ecosystem.

In the EMEA region, pricing pressures and health technology assessment requirements vary significantly between Western Europe’s stringent value-for-money demands and emerging markets in the Middle East and Africa where access constraints remain a barrier. Harmonization of regulatory standards through the European Medicines Agency and growing interest in public-private partnerships are creating new entry points for innovative formulations.

The Asia-Pacific region exhibits double-digit growth potential fueled by rising incidence of endocrine disorders, expanding hospital capacity, and proactive government policies in China, India and Southeast Asia aimed at local pharmaceutical manufacturing. Investment in cold-chain logistics and patient support programs is further enabling market penetration of long-acting and non-invasive delivery platforms.

Company Landscape: Competitive Positioning and Strategic Initiatives

The competitive landscape features major multinational companies, specialized biotechs and generic manufacturers, each pursuing distinct strategies. Novartis AG and Pfizer Inc. capitalize on global distribution networks and significant R&D investments to develop next-generation analogs, while Merck KGaA and Ipsen Pharma intensify focus on long-acting delivery and value-based pricing agreements. Crinetics Pharmaceuticals, Dauntless Pharmaceuticals, and Recordati Rare Diseases expand their pipelines through innovative formulation partnerships, and Cipla Limited, Teva Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries Limited leverage cost-effective manufacturing to address emerging markets.

Technology providers such as Bachem AG and Fresenius SE & Co. KGaA offer specialized peptide synthesis and contract development services, complemented by Camurus AB and Peptron, Inc., which drive advancements in bioconjugation and sustained release. Mid-sized firms including Abbiotec, Inc., Advanz Pharma Corp., Amryt Pharma PLC, Biodexa Pharmaceuticals PLC, and Pharmascience Inc. carve niche positions by focusing on targeted indications and regional distribution agreements. In parallel, CVS Health Corporation, Viatris Inc., and Wockhardt Ltd. integrate patient support services and supply chain optimization to reinforce their market presence, while Hybio Pharmaceutical Co., Ltd. and MedKoo Biosciences, Inc. invest heavily in R&D to refine nasal and oral delivery platforms.

Actionable Recommendations for Maximizing Market Opportunities

First, leaders should establish cross-functional innovation hubs that integrate R&D, regulatory affairs and commercial teams to accelerate new formulation pipelines and reduce time to market. Second, forging strategic partnerships with CDMOs and technology providers will ensure access to advanced peptide synthesis and bioconjugation capabilities, mitigating the impact of trade uncertainties and tariffs. Third, organizations must diversify supply chains by qualifying secondary suppliers, exploring near-shoring options, and implementing real-time logistics monitoring to bolster resilience.

Fourth, engaging proactively with payers and health technology assessment bodies to demonstrate real-world evidence and value-based outcomes will strengthen reimbursement positioning in both mature and emerging markets. Fifth, tailored patient support programs-leveraging digital platforms for adherence tracking and telemedicine integration-will enhance patient retention and differentiate offerings in competitive landscapes. Finally, prioritizing geographic expansion through targeted launches in high-growth regions and local partnerships will capture emerging demand while spreading commercial risk.

Conclusion: Strategic Imperatives for the Future of Somatostatin Analogs

In summary, the somatostatin analogs market is entering a phase of accelerated innovation and complexity, characterized by the rise of novel delivery modalities, evolving regulatory frameworks and growing patient expectations. To thrive, organizations must adopt holistic strategies that align scientific breakthroughs with commercial imperatives-balancing cost containment, supply chain agility and evidence-based value demonstration.

By harnessing segmentation insights, regional dynamics and competitive intelligence, industry stakeholders can refine their portfolio mix and optimize resource allocation. Strategic collaboration across the value chain-from peptide chemists to healthcare providers-will be essential to navigate tariff-induced headwinds and reimbursement challenges. Ultimately, success will hinge on a patient-centric approach that leverages technology, data and partnerships to deliver differentiated therapies with demonstrable clinical and economic benefits.

Market Segmentation & Coverage

This research report categorizes the Somatostatin Analogs Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Lanreotide
    • Depot Form
    • Pre-Filled Syringe
  • Octreotide
    • Immediate-Release Formulation
    • Long-Acting Formulation
  • Pasireotide
    • Intramuscular Form
    • Subcutaneous Form
  • Clinics
    • General Clinics
    • Specialty Clinics
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Research Institutes
    • Biotechnology Research
    • Pharmaceutical Research
  • Oncology
    • Acromegaly
    • Neuroendocrine Tumors
  • Pituitary Disorders
    • Cushing's Disease
    • Gigantism
  • Injectable
    • Solution Form
  • Nasal Spray
    • Direct Nasal Application
  • Oral
    • Pill Form
      • Controlled Release
      • Immediate Release
  • Bioconjugation Methods
    • Peptide Backbone Modification
  • Chemical Synthesis
    • Liquid-Phase Synthesis
    • Solid Phase Synthesis
  • Recombinant DNA Technology
    • Eukaryotic Systems
    • Prokaryotic Systems
  • Adult Population
    • Elderly
    • Working Professionals
  • Pediatric Population
    • Adolescent
    • Pre-Adolescent

This research report categorizes the Somatostatin Analogs Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Somatostatin Analogs Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbiotec, Inc.
  • Advanz Pharma Corp.
  • Amryt Pharma PLC by Chiesi Farmaceutici S.p.A.
  • Bachem AG
  • Biodexa Pharmaceuticals PLC
  • Camurus AB
  • Cipla Limited
  • Crinetics Pharmaceuticals, Inc.
  • CVS Health Corporation
  • Dauntless Pharmaceuticals, Inc.
  • Fresenius SE & Co. KGaA
  • Hybio Pharmaceutical Co., Ltd.
  • Ipsen Pharma
  • MedKoo Biosciences, Inc.
  • Merck KGaA
  • Novartis AG
  • Peptron, Inc.
  • Pfizer Inc.
  • Pharmascience Inc.
  • Recordati Rare Diseases, Inc.
  • Sun Pharmaceutical Industries Limited
  • Teijin Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Wockhardt Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Somatostatin Analogs Market, by Drug Type
8.1. Introduction
8.2. Lanreotide
8.2.1. Depot Form
8.2.2. Pre-Filled Syringe
8.3. Octreotide
8.3.1. Immediate-Release Formulation
8.3.2. Long-Acting Formulation
8.4. Pasireotide
8.4.1. Intramuscular Form
8.4.2. Subcutaneous Form
9. Somatostatin Analogs Market, by End-User
9.1. Introduction
9.2. Clinics
9.2.1. General Clinics
9.2.2. Specialty Clinics
9.3. Hospitals
9.3.1. Private Hospitals
9.3.2. Public Hospitals
9.4. Research Institutes
9.4.1. Biotechnology Research
9.4.2. Pharmaceutical Research
10. Somatostatin Analogs Market, by Application
10.1. Introduction
10.2. Oncology
10.2.1. Acromegaly
10.2.2. Neuroendocrine Tumors
10.3. Pituitary Disorders
10.3.1. Cushing's Disease
10.3.2. Gigantism
11. Somatostatin Analogs Market, by Formulation
11.1. Introduction
11.2. Injectable
11.2.1. Solution Form
11.3. Nasal Spray
11.3.1. Direct Nasal Application
11.4. Oral
11.4.1. Pill Form
11.4.1.1. Controlled Release
11.4.1.2. Immediate Release
12. Somatostatin Analogs Market, by Technology Used
12.1. Introduction
12.2. Bioconjugation Methods
12.2.1. Peptide Backbone Modification
12.3. Chemical Synthesis
12.3.1. Liquid-Phase Synthesis
12.3.2. Solid Phase Synthesis
12.4. Recombinant DNA Technology
12.4.1. Eukaryotic Systems
12.4.2. Prokaryotic Systems
13. Somatostatin Analogs Market, by Patient Demographics
13.1. Introduction
13.2. Adult Population
13.2.1. Elderly
13.2.2. Working Professionals
13.3. Pediatric Population
13.3.1. Adolescent
13.3.2. Pre-Adolescent
14. Americas Somatostatin Analogs Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Somatostatin Analogs Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Somatostatin Analogs Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Abbiotec, Inc.
17.3.2. Advanz Pharma Corp.
17.3.3. Amryt Pharma PLC by Chiesi Farmaceutici S.p.A.
17.3.4. Bachem AG
17.3.5. Biodexa Pharmaceuticals PLC
17.3.6. Camurus AB
17.3.7. Cipla Limited
17.3.8. Crinetics Pharmaceuticals, Inc.
17.3.9. CVS Health Corporation
17.3.10. Dauntless Pharmaceuticals, Inc.
17.3.11. Fresenius SE & Co. KGaA
17.3.12. Hybio Pharmaceutical Co., Ltd.
17.3.13. Ipsen Pharma
17.3.14. MedKoo Biosciences, Inc.
17.3.15. Merck KGaA
17.3.16. Novartis AG
17.3.17. Peptron, Inc.
17.3.18. Pfizer Inc.
17.3.19. Pharmascience Inc.
17.3.20. Recordati Rare Diseases, Inc.
17.3.21. Sun Pharmaceutical Industries Limited
17.3.22. Teijin Limited
17.3.23. Teva Pharmaceutical Industries Ltd.
17.3.24. Viatris Inc.
17.3.25. Wockhardt Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. SOMATOSTATIN ANALOGS MARKET MULTI-CURRENCY
FIGURE 2. SOMATOSTATIN ANALOGS MARKET MULTI-LANGUAGE
FIGURE 3. SOMATOSTATIN ANALOGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY TECHNOLOGY USED, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY TECHNOLOGY USED, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. SOMATOSTATIN ANALOGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. SOMATOSTATIN ANALOGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SOMATOSTATIN ANALOGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DEPOT FORM, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY IMMEDIATE-RELEASE FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY LONG-ACTING FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY INTRAMUSCULAR FORM, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY SUBCUTANEOUS FORM, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY BIOTECHNOLOGY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PHARMACEUTICAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ACROMEGALY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PITUITARY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CUSHING'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY GIGANTISM, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PITUITARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY SOLUTION FORM, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DIRECT NASAL APPLICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PILL FORM, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PILL FORM, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY BIOCONJUGATION METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PEPTIDE BACKBONE MODIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY BIOCONJUGATION METHODS, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY SOLID PHASE SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY EUKARYOTIC SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PROKARYOTIC SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ADULT POPULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY WORKING PROFESSIONALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PEDIATRIC POPULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PRE-ADOLESCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PEDIATRIC POPULATION, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY PITUITARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY PILL FORM, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY BIOCONJUGATION METHODS, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY PEDIATRIC POPULATION, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY PITUITARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY PILL FORM, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY BIOCONJUGATION METHODS, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY PEDIATRIC POPULATION, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY PITUITARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY PILL FORM, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY BIOCONJUGATION METHODS, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY PEDIATRIC POPULATION, 2018-2030 (USD MILLION)
TABLE 145. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 146. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, 2018-2030 (USD MILLION)
TABLE 147. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, 2018-2030 (USD MILLION)
TABLE 148. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, 2018-2030 (USD MILLION)
TABLE 149. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 151. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 152. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 153. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 154. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 155. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY PITUITARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 156. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 157. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 158. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 159. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 160. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY PILL FORM, 2018-2030 (USD MILLION)
TABLE 161. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 162. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY BIOCONJUGATION METHODS, 2018-2030 (USD MILLION)
TABLE 163. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 164. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 165. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 166. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 167. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY PEDIATRIC POPULATION, 2018-2030 (USD MILLION)
TABLE 168. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 169. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, 2018-2030 (USD MILLION)
TABLE 170. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, 2018-2030 (USD MILLION)
TABLE 171. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, 2018-2030 (USD MILLION)
TABLE 172. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 173. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 174. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 175. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 176. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 178. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY PITUITARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 179. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 180. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 181. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 182. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 183. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY PILL FORM, 2018-2030 (USD MILLION)
TABLE 184. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 185. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY BIOCONJUGATION METHODS, 2018-2030 (USD MILLION)
TABLE 186. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 187. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 188. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 189. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 190. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY PEDIATRIC POPULATION, 2018-2030 (USD MILLION)
TABLE 191. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 192. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, 2018-2030 (USD MILLION)
TABLE 193. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, 2018-2030 (USD MILLION)
TABLE 194. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, 2018-2030 (USD MILLION)
TABLE 195. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 197. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 198. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 199. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 201. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY PITUITARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 202. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 203. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 204. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 205. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 206. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY PILL FORM, 2018-2030 (USD MILLION)
TABLE 207. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 208. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY BIOCONJUGATION METHODS, 2018-2030 (USD MILLION)
TABLE 209. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 210. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 211. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 212. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 213. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY PEDIATRIC POPULATION, 2018-2030 (USD MILLION)
TABLE 214. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 215. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 216. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, 2018-2030 (USD MILLION)
TABLE 218. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, 2018-2030 (USD MILLION)
TABLE 219. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 220. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 221. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 222. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 223. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 224. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 225. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY PITUITARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 226. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 227. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 228. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 229. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 230. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY PILL FORM, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY BIOCONJUGATION METHODS, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY PEDIATRIC POPULATION, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 239. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 240. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, 2018-2030 (USD MILLION)
TABLE 241. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, 2018-2030 (USD MILLION)
TABLE 242. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, 2018-2030 (USD MILLION)
TABLE 243. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 244. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 245. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 246. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 247. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 248. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 249. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY PITUITARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 250. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 251. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 252. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 253. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 254. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY PILL FORM, 2018-2030 (USD MILLION)
TABLE 255. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 256. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY BIOCONJUGATION METHODS, 2018-2030 (USD MILLION)
TABLE 257. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 258. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 259. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY PEDIATRIC POPULATION, 2018-2030 (USD MILLION)
TABLE 262. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 263. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, 2018-2030 (USD MILLION)
TABLE 264. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, 2018-2030 (USD MILLION)
TABLE 265. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, 2018-2030 (USD MILLION)
TABLE 266. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 267. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 268. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 269. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 270. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 271. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 272. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY PITUITARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 273. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 274. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 275. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 276. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 277. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY PILL FORM, 2018-2030 (USD MILLION)
TABLE 278. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 279. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY BIOCONJUGATION METHODS, 2018-2030 (USD MILLION)
TABLE 280. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 281. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 282. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 283. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 284. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY PEDIATRIC POPULATION, 2018-2030 (USD MILLION)
TABLE 285. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 286. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, 2018-2030 (USD MILLION)
TABLE 287. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, 2018-2030 (USD MILLION)
TABLE 288. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, 2018-2030 (USD MILLION)
TABLE 289. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 290. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 291. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 292. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 293. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 294. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 295. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY PITUITARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 296. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 297. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 298. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 299. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 300. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY PILL FORM, 2018-2030 (USD MILLION)
TABLE 301. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 302. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY BIOCONJUGATION METHODS, 2018-2030 (USD MILLION)
TABLE 303. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 304. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 305. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 306. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 307. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY PEDIATRIC POPULATION, 2018-2030 (USD MILLION)
TABLE 308. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 309. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, 2018-2030 (USD MILLION)
TABLE 310. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, 2018-2030 (USD MILLION)
TABLE 311. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, 2018-2030 (USD MILLION)
TABLE 312. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 313. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 314. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY PITUITARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 319. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 321. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 322. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 323. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY PILL FORM, 2018-2030 (USD MILLION)
TABLE 324. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 325. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY BIOCONJUGATION METHODS, 2018-2030 (USD MILLION)
TABLE 326. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 327. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 328. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 329. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 330. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY PEDIATRIC POPULATION, 2018-2030 (USD MILLION)
TABLE 331. JAPAN SOMATOSTATIN ANALOGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 332. JAPAN SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, 2018-2030 (USD MILLION)
TABLE 333. JAPAN SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, 2018-2030 (USD MILLION)
TABLE 334. JAPAN SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, 2018-2030 (USD MILLION)
TABLE 335. JAPAN SOMATOSTATIN ANALOGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 336. JAPAN SOMATOSTATIN ANALOGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 337. JAPAN SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 338. JAPAN SOMATOSTATIN ANALOGS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 339. JAPAN SOMATOSTATI

Companies Mentioned

  • Abbiotec, Inc.
  • Advanz Pharma Corp.
  • Amryt Pharma PLC by Chiesi Farmaceutici S.p.A.
  • Bachem AG
  • Biodexa Pharmaceuticals PLC
  • Camurus AB
  • Cipla Limited
  • Crinetics Pharmaceuticals, Inc.
  • CVS Health Corporation
  • Dauntless Pharmaceuticals, Inc.
  • Fresenius SE & Co. KGaA
  • Hybio Pharmaceutical Co., Ltd.
  • Ipsen Pharma
  • MedKoo Biosciences, Inc.
  • Merck KGaA
  • Novartis AG
  • Peptron, Inc.
  • Pfizer Inc.
  • Pharmascience Inc.
  • Recordati Rare Diseases, Inc.
  • Sun Pharmaceutical Industries Limited
  • Teijin Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Wockhardt Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Somatostatin Analogs - Global Strategic Business Report - Product Image

Somatostatin Analogs - Global Strategic Business Report

  • Report
  • 94 Pages
  • Global
From
Somatostatin Analogs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Somatostatin Analogs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Somatostatin Analogs Market Report 2025 - Product Image

Somatostatin Analogs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Somatostatin Analogs Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Somatostatin Analogs Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Neuroendocrine Tumors (NETs) Market (2024 Edition): Analysis By Therapy (Somatostatin Analogs (SSAs), Targeted Therapy, Others), By Route of Administration, By Indication, By End User, By Region: Market Insights and Forecast (2020-2030) - Product Image

Neuroendocrine Tumors (NETs) Market (2024 Edition): Analysis By Therapy (Somatostatin Analogs (SSAs), Targeted Therapy, Others), By Route of Administration, By Indication, By End User, By Region: Market Insights and Forecast (2020-2030)

  • Report
  • 300 Pages
  • Global
From

About the Somatostatin Analogs Market

Somatostatin Analogs are a class of drugs used in the treatment of oncology. They are used to inhibit the release of hormones, such as growth hormone, which can be overproduced in certain types of cancer. Somatostatin Analogs are used to treat a variety of cancers, including neuroendocrine tumors, carcinoid tumors, and pancreatic islet cell tumors. They are also used to treat acromegaly, a condition caused by excessive growth hormone production. Somatostatin Analogs are administered either intravenously or subcutaneously, depending on the type of cancer being treated. The Somatostatin Analogs market is a rapidly growing segment of the oncology drugs market. It is driven by the increasing prevalence of cancer, as well as the development of new and improved drugs. The market is expected to continue to grow in the coming years, as more drugs are developed and approved for use. Some of the major companies in the Somatostatin Analogs market include Novartis, Pfizer, Merck, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.